glp-1 obesity drug study august 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo A network meta-analysis backed weight-loss

Description

If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration

Book Now No Hidden Fees, No Gimmicks Lets find out if Weight Loss Injections are a fit for your goals

Circulation 2021;143:1157-72.ArticlePubMedPMC 7

This program includes: 1-on-1 health coaching: Patients can connect with trained health coaches for motivation, habit-building, mindset support, and lifestyle guidance